Experimental study of iodine-131 labeling of a novel tumor-targeting peptide, TFMP-Y4, in the treatment of hepatocellular carcinoma with internal irradiation
<sup>131</sup>I-Caerin 1.1 and <sup>131</sup>I-TFMP-Y4 significantly inhibited the proliferation of Hepg2 cells in vitro and in vivo. In addition, <sup>131</sup>I-TFMP-Y4 can reduce adverse reactions during treatment.
Authors
- Weiwei Ren (ORCID: https://orcid.org/0000-0003-2101-0833)
- Zhuanming Chen
- Jinhe Zhang (ORCID: https://orcid.org/0000-0001-5770-2976)
- Qi Lai (ORCID: https://orcid.org/0000-0003-1966-9292)
- Peipei Zhang (ORCID: https://orcid.org/0000-0003-4405-0432)
- Wenjie Liu (ORCID: https://orcid.org/0000-0002-4907-2465)
- Wenjuan Liu (ORCID: https://orcid.org/0009-0003-6048-5273)
- Yushan Li (ORCID: https://orcid.org/0009-0005-0468-0589)
- Yixuan Zhou (ORCID: https://orcid.org/0000-0002-5522-0671)
- Tongsheng Chen (ORCID: https://orcid.org/0000-0002-9036-6676)
- Jianwei Yuan (ORCID: https://orcid.org/0000-0002-3417-5410)
- Xiongying Liu
- Juan Du (ORCID: https://orcid.org/0000-0002-4474-1199)
Institutions
- Guangdong Pharmaceutical University (CN)
- Third Affiliated Hospital of Southern Medical University (CN)
- General Hospital of Guangzhou Military Command (CN)
- First People's Hospital of Foshan (CN)
- The People's Hospital of Guangxi Zhuang Autonomous Region (CN)
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1186/s12885-025-13666-3
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32